Abstract 180P
Background
Along with the prolonged survival of cancer patients in recent years comes another dilemma, multiple primary cancers (MPC), which rob cancer patients of their privilege to optimal treatments. Nonetheless, understanding the hereditary and postnatal predisposition of MPC is still in its infancy.
Methods
We included 47,550 cancer patients in UK Biobank. Hazardous and protective HLA alleles concerning MPC were recognized leveraging stepwise logistic regression, which was further validated by log-rank test and Cox proportional hazard model. Logistic regression was used to investigate the organ-specific association between HLA and MPC. Cox proportional hazard model was used to explore potential interventions.
Results
Two protective (DPA1*02:02 and DRB1*04:03) and four hazardous (A*26:01, A*24:03, DPB1*20:01 and DQB1*06:01) HLA alleles are significantly associated with MPC risk for male, whereas one protective (DRB5*01:01) and four hazardous (A*03:02, DRB1*08:03, DQB1*05:04, and DPB1*11:01) for female. Compared with patients without MPC-related HLA alleles, both male and female patients carrying protective HLA alleles have lower risk of MPC (HR, 0.67 [95% CI, 0.53-0.83] and HR, 0.84 [95% CI, 0.73-0.97], respectively), while those carrying hazardous HLA alleles have higher risk of MPC (HR, 1.31 [95% CI, 1.09-1.57] and HR, 1.55 [95% CI, 1.25-1.93], respectively). HLA alleles are associated with organ-specific MPC occurrence. Lower animal fat intake subsided (HR, 0.46 [95% CI, 0.26-0.82]) while unqualified vegetable fat intake increased MPC risk (HR, 2.23 [95% CI, 1.22-4.07]) for male cancer patients carrying hazardous HLA alleles. Lower free sugar intake subsided the risk of MPC for female patients carrying hazardous HLA alleles (HR, 0.34 [95% CI, 0.15-0.74]).
Conclusions
HLA alleles might help to understand the predisposition and organ-specific incidence of MPC. Intervention on diet could counteract the risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zhongyi Dong.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
155P - Exploring the utility of serum anti-tNASP antibodies as a screening biomarker in prostate, pancreatic, and ovarian cancer
Presenter: Oleg Alekseev
Session: Poster session 01
156P - The association between fibrotic endotypes, determined by pre-treatment serum levels of collagen metabolites, and survival outcomes in patients with pancreatic cancer
Presenter: Rasmus Pedersen
Session: Poster session 01
157P - CLDN18 fusions rather than expression is a biomarker related to the efficacy of paclitaxel in patients with ovarian metastasis of gastric cancer
Presenter: Pengfei Yu
Session: Poster session 01
158P - In silico analysis of HER2 enriched subtype and a HER2 index based on transcriptomic data of breast cancer compared to gastric and uterine serous carcinomas
Presenter: Arturo Gonzalez-Vilanova
Session: Poster session 01
159P - Better performance of pan-claudin18 antibodies on claudin18.2 detection in gastric adenocarcinoma than claudin18.2 specific antibody
Presenter: Shujuan NI
Session: Poster session 01
161P - Biomarkers of neoadjuvant combinational therapy for locally advanced gastric or gastroesophageal junction adenocarcinoma
Presenter: Yue Wang
Session: Poster session 01
162P - MR imaging biomarkers profiles in patients with prostate cancer treated with androgen deprivation therapy
Presenter: Angel Luis Sanchez Iglesias
Session: Poster session 01
163P - Genomic alterations in circulating tumor DNA (ctDNA) and response to ABBV-400 treatment in patients with advanced solid tumors
Presenter: Jair Bar
Session: Poster session 01
164P - Early evaluation of effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer
Presenter: Astrid Kramer
Session: Poster session 01